医学
强力霉素
阴道出血
子宫内膜增生
妇科
宫腔镜检查
激素替代疗法(女性对男性)
异型性
产科
泌尿科
子宫内膜
雌激素
内科学
怀孕
睾酮(贴片)
病理
生物
遗传学
作者
C Quéreux,Bruno Pornel,Christine Bergeron,Alex S. Ferenczy
出处
期刊:Maturitas
[Elsevier BV]
日期:2005-07-26
卷期号:53 (3): 299-305
被引量:14
标识
DOI:10.1016/j.maturitas.2005.05.015
摘要
Objectives The aim of the study was to confirm the endometrial safety and describe the bleeding profile of continuous combined 1 mg 17β-oestradiol and 5 mg dydrogesterone in post-menopausal women. Methods An open, multicentre study was carried out in 290 healthy, non-hysterectomised post-menopausal women receiving oral continuous combined 1 mg 17β-oestradiol and 5 mg dydrogesterone (Femoston®-conti) for 1 year. Aspiration endometrial biopsies were performed at baseline and at the end of the study; those classified as hyperplasia or malignancy were considered treatment failures. Results Only one woman developed simple hyperplasia without atypia at the end of the study; the treatment failure rate was therefore 0.4%. Cross-sectional analysis showed that the percentage of women without bleeding increased from 71% during the first cycle to around 80% by the end of the study. Approximately 50% of the bleeding episodes occurred in the form of spotting; severe bleeding was rare and only seven women withdrew prematurely from the study due to uterine bleeding. Overall, 41% of the women were amenorrhoeic throughout the study. Conclusions Continuous combined 1 mg 17β-oestradiol and 5 mg dydrogesterone provides excellent endometrial safety and is associated with an acceptable bleeding profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI